Eli Lilly and Incyte's Olumiant Helps Eczema Patients in a Late-Stage Clinical Trial
In a quest to expand the usage of Olumiant, Eli Lilly (NYSE: LLY) and Incyte (NASDAQ: INCY) have shown the drug can help patients with atopic dermatitis, commonly referred to as eczema, when used in combination with topical corticosteroids. All the patients had already failed treatment with cyclosporine, the first-line generic drug used to treat the disease.
After 16 weeks of treatment, 31.5% of patients taking the highest dose of the drug had at least a 75% or greater change from baseline in their Eczema Area and Severity Index score (EASI75), while only 17.2% of patients taking placebo met the EASI75 goal. The healthcare companies also tested two other doses of the drug, with the middle dose helping 27.6% of patients and the low dose helping 22.6% of patients, but neither dose was statistically better than placebo.
Image source: Getty Images.
Source Fool.com
